We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Estimation Of Plasma Epidermal Growth Factor Receptor (Egfr) Mutation Status And Its Correlation With Tumor Tissue Egfr Mutation Status In Advanced Non-Small Cell Lung Cancer (Nsclc) Patients.
- Authors
Kannan, Thiruvengadasamy; Bhargavi, D.; Sarma, P. V. G. K.
- Abstract
Background: Patients with NSCLC harboring activating EGFR mutations respond to treatment with EGFR tyrosine kinase inhibitors (TKIs). The aim of this study was to determine whether tumor tissue EGFR analysis can be replaced with plasma EGFR analysis to assess mutation status. Methods: We prospectively evaluated EGFR gene mutation status (exons 18, 19, 20 and 21) in paired tissue and plasma from 68 advanced NSCLC patients (before starting anticancer treatment) during the period, May 2016 to May 2017 using Real Time based Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) assay and Allele specific PCR techniques respectively. Concordance and discordance rates were assessed. Results: Among 68 NSCLC patients, PCR results were obtained in 62/68 (91%) of biopsies and all 68/68(100%) plasma samples. EGFR mutations were identified in 14/62(23%) biopsy samples and 27/68(40%) plasma samples. Most common mutation identified in both tissue and plasma was exon 19 deletion. Both tissue and plasma EGFR mutations were more common in never smokers (P=0.04 and 0.02 respectively).The overall concordance of EGFR mutation status between tissue and plasma reached 66% (41/62) (Kappa coefficient: 0.24; P=0.038). The sensitivity, specificity, positive and negative predictive values of plasma EGFR detection were 64.3%, 66.7%, 36% and 86.5% respectively. Conclusions: EGFR gene mutation analysis of plasma is feasible with allele specific PCR assays with a high negative predictive value. It can be considered in frail patients not suitable for repeat biopsy when tissue material is not available. But further investigation is required to determine whether plasma sample can be considered for determining EGFR mutation status in future.
- Subjects
EPIDERMAL growth factor receptors; NON-small-cell lung carcinoma; PROTEIN-tyrosine kinases
- Publication
Journal of Cancer Research & Therapeutics, 2017, Vol 13, pS116
- ISSN
0973-1482
- Publication type
Article